New treatment may improve survival rates for advanced breast cancer patients
The new treatment involved a combination of two drugs, pembrolizumab and trastuzumab, which were administered to patients with advanced breast cancer who had already undergone at least one previous treatment. Pembrolizumab is an immunotherapy drug that helps to activate the body's immune system to attack cancer cells, while trastuzumab is a targeted therapy drug that blocks the growth of cancer cells. The combination of the two drugs showed positive results, with improved survival rates observed in patients who received the treatment.
Several studies were conducted to investigate the effectiveness of the pembrolizumab and trastuzumab combination. In one study, 148 patients with HER2-positive advanced breast cancer were randomly assigned to receive either pembrolizumab and trastuzumab or the chemotherapy drug capecitabine. The patients who received pembrolizumab and trastuzumab had a significantly longer progression-free survival, which is the length of time that a patient's cancer does not progress, compared to those who received capecitabine.
Another study found that the pembrolizumab and trastuzumab combination was also effective in treating patients with triple-negative breast cancer, a more aggressive form of breast cancer that currently has limited treatment options. The study involved 49 patients with triple-negative breast cancer who had already received at least one previous treatment. The patients who received pembrolizumab and trastuzumab had a response rate of 27.5%, which means that their tumors had either shrunk or disappeared completely.
While the results of these studies are promising, further research is needed to fully understand the potential of the pembrolizumab and trastuzumab combination in treating advanced breast cancer. Additional clinical trials are currently underway to investigate this treatment further.
In addition to pembrolizumab and trastuzumab, there are also other promising treatment options for advanced breast cancer. These include new targeted therapy drugs, which specifically target the cancer cells, and immunotherapy drugs, which help the body's immune system to fight cancer. There are also ongoing efforts to develop a vaccine that could prevent breast cancer from occurring in the first place.
It is important to remember that each person's breast cancer is unique and may require a personalized approach to treatment. Women with advanced breast cancer should work closely with their healthcare team to determine the best treatment options for their individual circumstances.
In conclusion, the new treatment involving a combination of pembrolizumab and trastuzumab is a promising development in the treatment of advanced breast cancer, with the potential to improve survival rates for patients. While further research is needed, this new approach offers hope for women with advanced breast cancer and their families. It is essential that we continue to invest in breast cancer research and support the development of new treatments. By working together, we can make breast cancer a disease of the past.